<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600079</url>
  </required_header>
  <id_info>
    <org_study_id>V211-024</org_study_id>
    <secondary_id>8003.016</secondary_id>
    <nct_id>NCT01600079</nct_id>
  </id_info>
  <brief_title>ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)</brief_title>
  <official_title>Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of
      herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared
      to a cohort of unvaccinated participants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2012</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79 ≥80) at Vaccination</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts by Time since Vaccination</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Postherpetic Neuralgia in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79, ≥80) at Vaccination</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Postherpetic Neuralgia in Vaccinated and Unvaccinated Cohorts by Time since Vaccination</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Herpes Zoster</condition>
  <condition>Shingles</condition>
  <arm_group>
    <arm_group_label>Vaccinated Cohort</arm_group_label>
    <description>Participants vaccinated with at least one dose of ZOSTAVAX™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unvaccinated Comparison Cohort</arm_group_label>
    <description>Participants who are not yet vaccinated with any zoster vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZOSTAVAX™</intervention_name>
    <description>ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use</description>
    <arm_group_label>Vaccinated Cohort</arm_group_label>
    <other_name>Zoster Vaccine Live</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Members of Kaiser Permanente Northern California (KPNC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with continuous Kaiser Permanente Northern California (KPNC) membership
             since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment
             in KPNC before their study start date

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Varicella-zoster vaccine</keyword>
  <keyword>herpes zoster</keyword>
  <keyword>shingles</keyword>
  <keyword>Varicella-zoster virus</keyword>
  <keyword>postherpetic neuralgia</keyword>
  <keyword>Herpesviridae Infections</keyword>
  <keyword>DNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

